Molecular diagnostics startup Swift Biosciences Inc. has pulled in a $3 million Series A investment.
The Ann Arbor, Michigan-based company will sell molecular biology reagents, which help scientists and doctors conduct genetic tests to identify whether patients are susceptible to specific diseases.
Reagents are chemicals used in lab settings to determine whether a chemical reaction has occurred, or to bring about a reaction.
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
Swift plans to use the funding to speed up product development and testing, according to a statement from the company.
The round was led by Houston-based DFJ Mercury, and included participation from several individual investors.
Swift’s CEO, David Olson, is the former chief scientific officer for Ann Arbor-based device startup Accuri Cytometers, which recently raised $6 million.